Baker Bros. Advisors Adds $17M in Evommune, Inc. ($EVMN)
Key Points
- Wall Street's consensus rating on $EVMN is Strong Buy and an average price target of $52.25.
- $EVMN last traded around $19.83.
Baker Bros. Advisors acquired a new position in Evommune, Inc. ($EVMN), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 847,390 shares of Evommune, Inc.. Baker Bros. Advisors's holdings in Evommune, Inc. were worth $16.80 million as of its most recent filing.
Evommune, Inc. ($EVMN) Stock
Evommune, Inc. Earnings
Analysts Set New Price Targets
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.